Neuroinflammation and neuroprotection: An update on (future) neurotrophin-related strategies in multiple sclerosis treatment

Current Medicinal Chemistry

Volumn 18, Issue 12, 2011, Pages 1775-1784

  De Santi, L ^a   Polimeni, G ^a   Cuzzocrea, S ^a   Esposito, E ^a   Sessa, E ^a   Annunziata, P ^b   Bramanti, P ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; BDNF; Immunomodulatory drugs; Multiple sclerosis; Neuroinflammation; Neuroprotection; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAZOLE DERIVATIVE; CEP 1347; K 252; MINOCYCLINE; NEUROTROPHIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CELL SURVIVAL; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; T LYMPHOCYTE;

AUTOIMMUNITY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS;

EID: 79955684278     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795496881     Document Type: Article

References (149)

1. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2008, 372(9648), 1502-17.
2. Rieckmann, P.; Mäurer, M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr. Opin. Neurol., 2002, 15(3), 361-70. (Pubitemid 34596903)
3. Hammarberg, H.; Lidman, O.; Lundberg, C.; Eltayeb, S.Y.; Gielen, A.W.; Muhallab, S. et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci., 2000, 20(14), 5283-91. (Pubitemid 30457725)
4. Moalem, G.; Leibowitz-Amit, R.; Yoles, E.; Mor, F.; Cohen, I.R.; Schwartz, M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med., 1999, 5(1), 49-55. (Pubitemid 29050998)
5. Graber, J.J.; Dhib-Jalbut, S. Protective autoimmunity in the nervous system. Pharmacol. Ther., 2009, 121(2), 147-59.
6. Hohlfeld, R.; Kerschensteiner, M.; Stadelmann, C.; Lassmann, H.; Wekerle, H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol. Sci, 2006, 27 Suppl 1, S1-7.
7. Kerschensteiner, M.; Stadelmann, C.; Dechant, G.; Wekerle, H.; Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol., 2003, 53(3), 292-304. (Pubitemid 36258633)
8. Kerschensteiner, M.; Gallmeier, E.; Behrens, L.; Leal, V.V.; Misgeld, T.; Klinkert.; W.E., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med., 1999, 189(5), 865-70. (Pubitemid 29189691)
9. Stadelmann, C.; Kerschensteiner, M.; Misgeld. T.; Brück, W.; Hohlfeld, R.; Lassmann, H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain, 2002, 125(Pt 1), 75-85. (Pubitemid 34084038)
10. Ziemssen, T.; Kümpfel, T.; Klinkert, W.E.F.; Neuhaus, O.; Hohlfeld, R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain, 2002, 125(Pt 11), 2381-91. (Pubitemid 35303499)
11. Oksenberg, J.R.; Hauser, S.L. Genetics of multiple sclerosis. Neurol. Clin., 2005, 23(1), 61-75. (Pubitemid 40126915)
12. Iwakura, Y.; Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest., 2006, 116(5), 1218-22.
13. Matusevicius, D.; Kivisäkk, P.; He B, Kostulas, N.; Ozenci, V.; Fredrikson. S. et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler., 1999, 5(2), 101-4. (Pubitemid 29186827)
14. Lock, C.; Hermans, G.; Pedotti, R.; Brendolan, A.; Schadt, E.; Garren, H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med., 2002, 8(5), 500-8. (Pubitemid 34546753)
15. Vaknin-Dembinsky, A.; Balashov, K.; Weiner, H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol., 2006, 176(12), 7768-74. (Pubitemid 43849078)
16. Babbe, H.; Roers, A.; Waisman, A.; Lassmann, H.; Goebels, N.; Hohlfeld, R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med., 2000, 192(3), 393-404. (Pubitemid 30629164)
17. Ji, Q.; Goverman, J. Experimental autoimmune encephalomyelitis mediated by CD8+ T cells. Ann. N. Y. Acad. Sci., 2007, 1103, 157-166. (Pubitemid 46791117)
18. McFarland, H.F.; Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol., 2007, 8(9), 913-9. (Pubitemid 47300005)
19. Korn, T.; Reddy, J.; Gao, W.; Bettelli, E.; Awasthi, A.; Petersen, T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med., 2007, 13(4), 423-31. (Pubitemid 46559831)
20. Bielekova, B.; Catalfamo, M.; Reichert-Scrivner, S.; Packer, A.; Cerna, M.; Waldmann, T.A., et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Nat. Acad. Sci. U. S. A., 2006, 103(15), 5941-6.
21. Wesselborg, S.; Janssen, O.; Kabelitz, D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol., 1993, 150(10), 4338-45. (Pubitemid 23133710)
22. Zimmermann, K.C.; Bonzon, C.; Green, D.R. The machinery of programmed cell death. Pharmacol. Ther., 2001, 92(1), 57-70. (Pubitemid 34032022)
23. Macchi, B.; Matteucci, C.; Nocentini, U.; Caltagirone, C.; Mastino, A. Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport., 1999, 10(2), 399-402. (Pubitemid 29104820)
24. Zang, Y.C.; Kozovska, M.M.; Hong, J.; Li, S.; Mann, S.; Killian, J.M., et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol., 1999, 29(5), 1692-700. (Pubitemid 29224475)
25. Pender, M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet, 1998, 351(9107), 978-81. (Pubitemid 28138482)
26. Zipp, F. Apoptosis in multiple sclerosis. Cell. Tissue. Res., 2000, 301(1), 163-71. (Pubitemid 30459863)
27. Saresella, M.; Marventano, I.; Speciale, L.; Ruzzante, S.; Trabattoni, D.; Della Bella, S., et al. Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. J. Neuroimmunol., 2005, 166(1-2), 173-9. (Pubitemid 41074667)
28. Okuda, Y.; Apatoff, B.R.; Posnett, D.N. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J. Neuroimmunol., 2006, 171(1-2), 163-70. (Pubitemid 41832287)
29. Dhein, J.; Walczak, H.; Bäumler, C.; Debatin, K.M.; Krammer, P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 1995, 373(6513), 438-41.
30. Zipp, F.; Faber, E.; Sommer, N.; Müller, C.; Dichgans, J.; Krammer, P.H., et al. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLADR2. J. Neuroimmunol., 1998, 81(1-2), 168-72.
31. De Santi, L.; Cantalupo, L.; Tassi, M.; Raspadori, D.; Cioni, C.; Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis. J. Neurol. Sci., 2009, 277(1-2), 65-70.
32. Allen, I.V.; McQuaid, S.; Mirakhur, M.; Nevin, G. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol. Sci., 2001, 22(2), 141-4. (Pubitemid 33771280)
33. Gravel, C.; Götz, R.; Lorrain, A.; Sendtner, M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat. Med., 1997, 3(7), 765-70. (Pubitemid 27298721)
34. McTigue, D.M.; Horner, P.J.; Stokes, B.T.; Gage, F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci., 1998, 18(14), 5354-65. (Pubitemid 28311952)
35. Kil, K.; Zang, Y.C.; Yang, D.; Markowski, J.; Fuoco, G.S.; Vendetti, G.C., et al. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J. Neuroimmunol., 1999, 98(2), 201-7. (Pubitemid 29317546)
36. Bieber, A.J.; Kerr, S.; Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann. Neurol., 2003, 53(5), 680-4. (Pubitemid 36529446)
37. Serpe, C.J.; Kohm, A.P.; Huppenbauer, C.B.; Sanders, V.M.; Jones, K.J. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J. Neurosci., 1999, 19(11), RC7.
38. Novikov, L.; Novikova, L.; Kellerth, J.O. Brain-derived neurotrophic factor promotes survival and blocks nitric oxide synthase expression in adult rat spinal motoneurons after ventral root avulsion. Neurosci. Lett., 1995, 200(1), 45-8.
39. Kishino, A.; Ishige, Y.; Tatsuno, T.; Nakayama, C.; Noguchi, H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp. Neurol., 1997, 144(2), 273-86. (Pubitemid 27224556)
40. Kawakami, N.; Odoardi, F.; Ziemssen, T.; Bradl, M.; Ritter, T.; Neuhaus, O., et al. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. J. Immunol., 2005, 175(1), 69-81. (Pubitemid 40884303)
41. Burns, J.; Rosenzweig, A.; Zweiman, B.; Lisak, R.P. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell. Immunol., 1983, 81(2), 435-40. (Pubitemid 13017156)
42. Mendel, I.; Kerlero de Rosbo, N.; Ben-Nun, A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol., 1995, 25(7), 1951-9.
43. Rapalino, O.; Lazarov-Spiegler, O.; Agranov, E.; Velan, G.J.; Yoles, E.; Fraidakis, M., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med., 1998, 4(7), 814-21. (Pubitemid 28331023)
44. Schwartz, M.; Moalem, G.; Leibowitz-Amit, R.; Cohen, I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci., 1999, 22(7), 295-9. (Pubitemid 29307803)
45. Tobias, C.A.; Shumsky, J.S.; Shibata, M.; Tuszynski, M.H.; Fischer, I.; Tessler, A., et al. Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured spinal cord stimulates sprouting, partially rescues axotomized red nucleus neurons from loss and atrophy, and provides limited regeneration. Exp. Neurol., 2003, 184(1), 97-113. (Pubitemid 37444023)
46. Hauben, E.; Nevo, U.; Yoles, E.; Moalem, G.; Agranov, E.; Mor, F., et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet, 2000, 355(9200), 286-7. (Pubitemid 30068524)
47. Hauben, E.; Schwartz, M. Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol. Sci., 2003, 24(1), 7-12. (Pubitemid 36009283)
48. Baloh, R.H.; Enomoto, H.; Johnson, E.M.; Milbrandt J. The GDNF family ligands and receptors - implications for neural development. Curr. Opin. Neurobiol., 2000, 10(1), 103-10. (Pubitemid 30102862)
49. Lindvall, O.; Kokaia, Z.; Bengzon, J.; Elmér, E.; Kokaia, M. Neurotrophins and brain insults. Trends Neurosci., 1994, 17(11), 490-6. (Pubitemid 24321951)
50. Seidah, N.G.; Benjannet, S.; Pareek, S.; Chrétien, M.; Murphy, R.A. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett., 1996, 379(3), 247-50. (Pubitemid 26049450)
51. Cowan, W.M. Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu. Rev. Neurosci., 2001, 24, 551-600. (Pubitemid 32695239)
52. Bauer, S.; Kerr, B.J.; Patterson, P.H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat. Rev. Neurosci., 2007, 8(3), 221-32. (Pubitemid 46294661)
53. Klein, R.; Nanduri, V.; Jing, S.A.; Lamballe, F.; Tapley, P.; Bryant, S. et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell, 1991, 66(2), 395-403. (Pubitemid 121001376)
54. Klein, R.; Conway, D.; Parada, L.F.; Barbacid, M. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell, 1990, 61(4), 647-56.
55. Stoilov, P.; Castren, E.; Stamm, S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem. Biophys. Res. Commun., 2002, 290(3), 1054-65. (Pubitemid 34687470)
56. Liepinsh, E.; Ilag, L.L.; Otting, G.; Ibáñez, C,F. NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J., 1997, 16(16), 4999-5005. (Pubitemid 27348408)
57. Arévalo, J.C.; Wu, S.H. Neurotrophin signaling: many exciting surprises! Cell. Mol. Life Sci., 2006, 63(13), 1523-37. (Pubitemid 44156749)
58. Sarchielli, P.; Greco, L.; Stipa, A.; Floridi, A.; Gallai, V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J. Neuroimmunol., 2002, 132(1-2), 180-8. (Pubitemid 35333341)
59. Weinstock-Guttman, B.; Zivadinov, R.; Tamaño-Blanco, M.; Abdelrahman, N.; Badgett, D.; Durfee, J., et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J. Neuroimmunol., 2007, 188(1-2), 167-74. (Pubitemid 47103218)
60. Deloire-Grassin, M.S.; Brochet. B.; Quesson, B.; Delalande, C.; Dousset, V.; Canioni, P., et al. In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J. Neurol. Sci., 2000, 178(1), 10-6.
61. Ziemssen, T.; Kümpfel, T.; Klinkert, W.E.F.; Neuhaus, O.; Hohlfeld, R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain, 2002, 125(Pt 11), 2381-91. (Pubitemid 35303499)
62. Chen, M.; Valenzuela, R.M.; Dhib-Jalbut, S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci., 2003, 215(1- 2), 37-44. (Pubitemid 37279143)
63. Aharoni, R.; Kayhan, B.; Eilam, R.; Sela, M.; Arnon, R. Glatiramer acetatespecific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Nat. Acad. Sci. U. S. A., 2003, 100(24), 14157-62. (Pubitemid 37499207)
64. Benner, E.J.; Mosley, R.L.; Destache, C.J.; Lewis, T.B.; Jackson-Lewis, V.; Gorantla, S., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Nat. Acad. Sci. U. S. A., 2004, 101(25), 9435-40. (Pubitemid 38812892)
65. Gorantla, S.; Liu, J.; Sneller, H.; Dou, H.; Holguin, A.; Smith. L., et al. Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J. Immunol., 2007, 179(7), 4345-56.
66. Kipnis, J.; Nevo, U.; Panikashvili, D.; Alexandrovich, A.; Yoles, E.; Akselrod, S., et al. Therapeutic vaccination for closed head injury. J. Neurotrauma, 2003, 20(6), 559-69. (Pubitemid 36807900)
67. Frenkel, D.; Maron, R.; Burt, D.S.; Weiner, H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest., 2005, 115(9), 2423-33. (Pubitemid 41266204)
68. Blanco, Y.; Moral, EA.; Costa, M.; Gómez-Choco, M.; Torres-Peraza, J.F.; Alonso-Magdalena, L., et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci. Lett., 2006, 406(3), 270-5. (Pubitemid 44376571)
69. Lalive, P.H.; Kantengwa, S.; Benkhoucha, M.; Juillard, C.; Chofflon, M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J. Neuroimmunol., 2008, 197(2), 147-51.
70. Azoulay, D.; Mausner-Fainberg, K.; Urshansky, N.; Fahoum, F.; Karni, A. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. J. Neuroimmunol., 2009, 211(1-2), 114-9.
71. Gielen, A.; Khademi, M.; Muhallab, S.; Olsson, T.; Piehl, F. Increased brainderived neurotrophic factor expression in white blood cells of relapsingremitting multiple sclerosis patients. Scand. J. Immunol., 2003, 57(5), 493-7. (Pubitemid 36577910)
72. Petereit, H.F.; Lindemann, H.; Schoppe, S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult. Scler., 2003, 9(1), 16-20. (Pubitemid 36253690)
73. Caggiula, M.; Batocchi, A.P.; Frisullo, G.; Angelucci, F.; Patanella, A.K.; Sancricca, C., et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin. Immunol., 2006, 118(1), 77-82. (Pubitemid 43012049)
74. Sarchielli, P.; Zaffaroni, M.; Floridi, A.; Greco, L.; Candeliere, A.; Mattioni, A., et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon- beta 1a, and high doses of immunoglobulins. Mult. Scler., 2007, 13(3), 313-31. (Pubitemid 46705992)
75. De Santi, L.; Annunziata, P.; Sessa, E.; Bramanti, P. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neurol Sci., 2009, 287(1-2), 17-26.
76. Patanella, A.K.; Zinno, M.; Quaranta, D.; Nociti, V.; Frisullo, G.; Gainotti, G., et al. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J. Neurosci. Res., 2010, 88(5), 1106-1112
77. Lisak, R.P.; Benjamins, J.A.; Bealmear, B.; Yao, B.; Land, S.; Nedelkoska, L., et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures. Mult. Scler., 2006, 12(2), 149-68.
78. Lisak. R.P.; Benjamins, J.A.; Bealmear, B.; Nedelkoska, L.; Yao, B.; Land, S., et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J. Neuroinflammation, 2007, 4, 30.
79. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996; 19(11): 514-20. (Pubitemid 26359871)
80. Schuhmann, B.; Dietrich, A.; Sel, S.; Hahn, C.; Klingenspor, M.; Lommatzsch, M., et al. A role for brain-derived neurotrophic factor in B cell development. J. Neuroimmunol., 2005, 163(1-2), 15-23. (Pubitemid 40692945)
81. Bratke, K.; Maruschke, L.; Darowski, M.; Kuepper, M.; Braun, A.; Virchow, J.C., et al. A role for the neurotrophin receptor TrkB on maturing dendritic cells. J. Neuroimmunol., 2007, 189(1-2), 88-94. (Pubitemid 47379437)
82. Maroder, M.; Bellavia, D.; Meco, D.; Napolitano, M.; Stigliano, A.; Alesse, E., et al. Expression of trKB neurotrophin receptor during T cell development. Role of brain derived neurotrophic factor in immature thymocyte survival. J. Immunol., 1996, 157(7), 2864-72. (Pubitemid 126450041)
83. Garcia-Suarez, O., Blanco-Gelaz, M.A., Lopez, M.L., Germana, A., Cabo, R., Díaz-Esnal, B., et al. Massive lymphocyte apoptosis in the thymus of functionally deficient TrkB mice. J. Neuroimmunol., 2002, 129(1-2), 25-34. (Pubitemid 34874906)
84. Laurenzi, M.A.; Barbany, G.; Timmusk, T.; Lindgren, J.A.; Persson, H. Expression of mRNA encoding neurotrophins and neurotrophin receptors in rat thymus, spleen tissue and immunocompetent cells. Regulation of neurotrophin- 4 mRNA expression by mitogens and leukotriene B4. Eur. J. Biochem., 1994, 223(3), 733-41. (Pubitemid 24263154)
85. Lomen-Hoerth, C.; Shooter, E.M. Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues. J. Neurochem., 1995, 64(4), 1780-9.
86. D'Onofrio, M.; de Grazia, U.; Morrone, S.; Cuomo, L.; Spinsanti, P.; Frati, L., et al. Expression of neurotrophin receptors in normal and malignant B lymphocytes. Eur. Cytokine Net., 2000, 11(2), 283-91.
87. Labouyrie, E.; Dubus, P.; Groppi, A.; Mahon, F.X.; Ferrer, J.; Parrens, M., et al. Expression of neurotrophins and their receptors in human bone marrow. Am. J. Pathol., 1999, 154(2), 405-15. (Pubitemid 29094091)
88. Hannestad, J.; Levanti, M.B.; Vega, J.A. Distribution of neurotrophin receptors in human palatine tonsils: an immunohistochemical study. J. Neuroimmunol., 1995, 58(2), 131-7.
89. García-Suárez, O.; Hannestad, J.; Esteban, I.; Martínez del Valle, M.; Naves, F.J.; Vega, J.A. Neurotrophin receptor-like protein immunoreactivity in human lymph nodes. Anat. Rec., 1997, 249(2), 226-32. (Pubitemid 27426326)
90. Edling, A.E.; Nanavati, T.; Johnson, J.M.; Tuohy, V.K. Human and murine lymphocyte neurotrophin expression is confined to B cells. J. Neurosci. Res., 2004, 77(5), 709-17. (Pubitemid 39194612)
91. Schenone, A.; Gill, J.S.; Zacharias, D.A.; Windebank, A.J. Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. J. Neuroimmunol., 1996, 64(2), 141-9. (Pubitemid 26094631)
92. Besser, M.; Wank, R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J. Immunol., 1999, 162(11), 6303-6. (Pubitemid 29309346)
93. Douma, S.; Van Laar, T.; Zevenhoven, J.; Meuwissen, R.; Van Garderen, E.; Peeper, D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature, 2004, 430(7003), 1034-9.
94. Li, Z.; Beutel, G.; Rhein, M.; Meyer, J.; Koenecke, C.; Neumann, T., et al. High affinity neurotrophin receptors and ligands promote leukemogenesis. Blood, 2009, 113(9), 2028-37
95. Mitra, G.; Martin-Zanca, D.; Barbacid, M. Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc. Natl. Acad. Sci. U. S. A., 1987, 84(19), 6707-11. (Pubitemid 18025489)
96. Azoulay, D.; Vachapova, V.; Shihman, B.; Miler, A.; Karni, A. Lower brainderived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol., 2005, 167(1-2), 215-8. (Pubitemid 41242305)
97. Linker, R.; Lee, D-H.; Siglienti, I.; Gold, R. Is there a role for neurotrophins in the pathology of multiple sclerosis? J. Neurol., 2007, 254 (Suppl 1), 33-40.
98. Trojano, M.; Pellegrini, F.; Fuiani, A.; Paolicelli, D.; Zipoli, V.; Zimatore, G.B., et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol., 2007, 61(4), 300-6. (Pubitemid 46676729)
99. Goodin, D.S. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology, 2008, 71(24 Suppl 3), S8-13.
100. Bermel, R.A.; Rudick, R.A. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics, 2007, 4(4), 633-46.
101. Aharoni, R.; Herschkovitz, A.; Eilam, R.; Blumberg-Hazan, M.; Sela, M.; Bruck, W., et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(32), 11358-63.
102. Teitelbaum, D.; Aharoni, R.; Klinger, E.; Kreitman, R.; Raymond, E.; Malley, A., et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann. N. Y. Acad. Sci., 2004, 1029, 239-49. (Pubitemid 40298534)
103. Comi, G.; Filippi, M.; Wolinsky, J.S. European/Canadian multicenter, double- blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol., 2001, 49(3), 290-7. (Pubitemid 32202781)
104. Dabbert, D.; Rösner, S.; Krämer, M.; Schöll, U.; Tumani, H.; Mäder, M., et al. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett., 2000, 289(3), 205-8. (Pubitemid 30657974)
105. Ruggieri, M.; Avolio, C.; Livrea, P.; Trojano, M. Glatiramer acetate in multiple sclerosis: a review. CNS Drug. Rev., 2007, 13(2), 178-91. (Pubitemid 47052348)
106. Ziemssen, T.; Schrempf, W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int. Rev. Neurobiol., 2007, 79, 537-70.
107. Kipnis, J.; Yoles, E.; Porat, Z.; Cohen, A.; Mor, F.; Sela, M., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(13), 7446-51. (Pubitemid 30431483)
108. Biernacki, K.; Antel, J.P.; Blain, M.; Narayanan, S.; Arnold, D.L.; Prat, A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol., 2005, 62(4), 563-8. (Pubitemid 40489886)
109. Matute, C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol. Med., 2006, 12(7), 289-92. (Pubitemid 44110002)
110. Reynolds, A.; Laurie, C.; Mosley, R.L.; Gendelman, H.E. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol., 2007, 82, 297-325.
111. Smith, T.; Groom, A.; Zhu, B.; Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med., 2000, 6(1), 62-6. (Pubitemid 30048527)
112. Pitt, D.; Werner, P.; Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med., 2000, 6(1), 67-70. (Pubitemid 30048528)
113. Sarchielli, P.; Greco, L.; Floridi, A.; Gallai, V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch. Neurol., 2003, 60(8), 1082-8. (Pubitemid 36975795)
114. Kalkers, N.F.; Barkhof, F.; Bergers, E.; van Schijndel, R.; Polman, C.H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler., 2002, 8(6), 532-3. (Pubitemid 35396406)
115. Popovic, N.; Schubart, A.; Goetz, B.D.; Zhang, S.; Linington, C.; Duncan, I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol., 2002, 51(2), 215-23. (Pubitemid 34111444)
116. Brundula, V.; Rewcastle, N.B.; Metz, L.M.; Bernard, C.C.; Yong, V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain, 2002, 125(6), 1297-308. (Pubitemid 34587139)
117. Giuliani, F.; Fu, S.A.; Metz, L.M.; Yong, V.W. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol., 2005, 165(1-2), 83-91. (Pubitemid 40984625)
118. Giuliani, F.; Metz, L.M.; Wilson, T.; Fan, Y.; Bar-Or, A.; Yong, V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol., 2005, 158(1-2), 213-21. (Pubitemid 39626089)
119. Metz, L.M.; Zhang, Y.; Yeung, M.; Patry, D.G.; Bell, R.B.; Stoian, C.A., et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol., 2004, 55(5), 756. (Pubitemid 38544341)
120. Kloppenburg, M.; Verweij, C.L.; Miltenburg, A.M.; Verhoeven, A.J.; Daha, M.R.; Dijkmans, B.A., et al. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol., 1995, 102(3), 635-41. (Pubitemid 26013229)
121. Machado, L.S.; Kozak, A.; Ergul, A.; Hess, D.C.; Borlongan, C.V.; Fagan, S.C. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci., 2006, 7, 56.
122. Zhu, S.; Stavrovskaya, I.G.; Drozda, M.; Kim, B.Y.S.; Ona, V.; Li, M., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417(6884), 74-8. (Pubitemid 34498818)
123. Tikka, T.; Fiebich, B.L.; Goldsteins, G.; Keinanen, R.; Koistinaho, J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci., 2001, 21(8), 2580-8. (Pubitemid 32298200)
124. Tikka, T.M.; Koistinaho, J.E. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J. Immunol., 2001, 166(12), 7527-33. (Pubitemid 32525632)
125. Yong, V.W.; Giuliani, F.; Xue, M.; Bar-Or, A.; Metz, L.M. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology, 2007, 68(22 Suppl 3), S32-7. (Pubitemid 46848609)
126. Kase, H.; Iwahashi, K.; Nakanishi, S.; Matsuda, Y.; Yamada, K.; Takahashi, M., et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun., 1987, 142(2), 436-40. (Pubitemid 17003365)
127. Knüsel, B.; Hefti, F. K-252 compounds: modulators of neurotrophin signal transduction. J. Neurochem., 1992, 59(6), 1987-96.
128. Akinaga, S.; Ashizawa, T.; Gomi, K.; Ohno, H.; Morimoto, M.; Murakata, C., et al. Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action. Cancer Chemother. Pharmacol., 1992, 29(4), 266-72.
129. Chin, L.S.; Murray, S.F.; Zitnay, K.M.; Rami, B. K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction. Clin. Cancer Res., 1997, 3(5), 771-6. (Pubitemid 27244345)
130. Delsite, R.; Djakiew, D. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. J. Androl., 1996, 17(5), 481-90. (Pubitemid 26403608)
131. Perez-Pinera, P.; Hernandez, T.; García-Suárez, O.; de Carlos, F.; Germana, A.; Del Valle, M., et al. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Mol. Cell. Biochem., 2007, 295(1-2), 19-26. (Pubitemid 46157982)
132. Camoratto, A.M.; Jani, J.P.; Angeles, T.S.; Maroney, A.C.; Sanders, C.Y.; Murakata, C., et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int. J. Cancer, 1997, 72(4), 673-9. (Pubitemid 27356171)
133. George, D.J.; Dionne, C.A.; Jani, J.; Angeles, T.; Murakata, C.; Lamb, J., et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res., 1999, 59(10), 2395-401. (Pubitemid 29242288)
134. Undevia, S.D.; Vogelzang, N.J.; Mauer, A.M.; Janisch, L.; Mani, S.; Ratain, M.J. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs, 2004, 22(4), 449-58. (Pubitemid 39619821)
135. Saporito, M.S.; Hudkins, R.L.; Maroney, A.C. Discovery of CEP-1347/KT- 7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem., 2002, 40, 23-62.
136. Maroney, A.C.; Finn, J.P.; Connors, T.J.; Durkin, J.T.; Angeles, T.; Gessner, G., et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem., 2001, 276(27), 25302-8.
137. Saporito, M.S.; Brown, E.R.; Carswell, S.; DiCamillo, A.M.; Miller, M.S.; Murakata, C., et al. Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis. Neuroscience, 1998, 86(2), 461-72. (Pubitemid 28293925)
138. Bozyczko-Coyne, D.; O'Kane, T.M.; Wu, Z.L.; Dobrzanski, P.; Murthy, S.; Vaught, J.L., et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J. Neurochem., 2001, 77(3), 849-63. (Pubitemid 32466782)
139. Harris, C.A.; Deshmukh, M.; Tsui-Pierchala, B.; Maroney, A.C.; Johnson, E.M. Inhibition of the c-Jun N-terminal kinase signaling pathway by themixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J. Neurosci., 2002, 22(1), 103-13. (Pubitemid 34033488)
140. Saporito, M.S.; Brown, E.M.; Miller, M.S.; Carswell, S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4- phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. J. Pharmacol. Exp. Ther., 1999, 288(2), 421-7. (Pubitemid 29119647)
141. Lund, S.; Porzgen, P.; Mortensen, A.L.; Hasseldam, H.; Bozyczko-Coyne, D.; Morath, S., et al. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J. Neurochem., 2005, 92(6), 1439-51. (Pubitemid 40389213)
142. De Keyser, J.; Sulter, G.; Luiten, P.G. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci., 1999, 22(12), 535-40.
143. Hohlfeld, R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain, 1997, 120( Pt 5), 865-916.
144. Noseworthy, J.H.; Gold, R.; Hartung, H.P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr. Opin. Neurol., 1999, 12(3), 279-93. (Pubitemid 29378162)
145. Kramer, R.; Zhang, Y.; Gehrmann, J.; Gold, R.; Thoenen, H.; Wekerle, H. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat. Med., 1995, 1(11), 1162-6.
146. Makar, T.K.; Bever, C.T.; Singh, I.S.; Royal, W.; Sahu, S.N.; Sura, T.P., et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J. Neuroimmunol., 2009, 210(1-2), 40-51.
147. Flügel, A.; Willem, M.; Berkowicz, T.; Wekerle, H. Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat. Med., 1999, 5(7), 843-7. (Pubitemid 29318623)
148. Lazarovici, P.; Rasouly, D.; Friedman, L.; Tabekman, R.; Ovadia, H.; Matsuda, Y. K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Adv. Exp. Med. Biol., 1996, 391, 367-77.
149. Lopez-Diego, R.S.; Weiner, H.L. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat. Rev. Drug Discov., 2008, 7(11), 909-25.